Comparison of efficacy and toxicity of bevacizumab, endostar and apatinib in transgenic and human lung cancer xenograftzebrafish model.

Publisher: Nature Publishing Group Country of Publication: England NLM ID: 101563288 Publication Model: Electronic Cited Medium: Internet ISSN: 2045-2322 (Electronic) Linking ISSN: 20452322 NLM ISO Abbreviation: Sci Rep Subsets: MEDLINE

Original Publication: London : Nature Publishing Group, copyright 2011-

Angiogenesis Inhibitors/*therapeutic use ; Bevacizumab/*therapeutic use ; Carcinoma, Non-Small-Cell Lung/*drug therapy ; Endostatins/*therapeutic use ; Lung Neoplasms/*drug therapy ; Pyridines/*therapeutic use ; Recombinant Proteins/*therapeutic use; A549 Cells ; Angiogenesis Inhibitors/pharmacology ; Animals ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Bevacizumab/pharmacology ; Carcinoma, Non-Small-Cell Lung/metabolism ; Carcinoma, Non-Small-Cell Lung/pathology ; Disease Models, Animal ; Embryo, Nonmammalian/drug effects ; Embryo, Nonmammalian/metabolism ; Embryo, Nonmammalian/pathology ; Endostatins/pharmacology ; Humans ; Larva/anatomy & histology ; Larva/drug effects ; Larva/metabolism ; Lung Neoplasms/metabolism ; Lung Neoplasms/pathology ; Pemetrexed/pharmacology ; Pemetrexed/therapeutic use ; Pyridines/pharmacology ; Recombinant Proteins/pharmacology ; Transplantation, Heterologous ; Xenograft Model Antitumor Assays ; Zebrafish/anatomy & histology ; Zebrafish/growth & development ; Zebrafish/metabolism

The poor prognosis in non-small-cell lung cancer has driven the development of novel targeted therapies. Vascular endothelial growth factor is the most potent force in mediating tumor angiogenesis, and many angiogenesis inhibitors have been developed for oncology treatment. We performed a study to characterize the efficacy, safety and tumor suppression of three lung cancer related anti-angiogenic drugs (bevacizumab, endostar and apatinib) using transgenic zebrafish embryo and human lung cancer xenotransplantation model. All three drugs demonstrated remarkable angiogenesis and tumor inhibition effect in the zebrafish model, within the nonlethal dose range. Endostar and bevacizumab showed competitive anti-tumor efficacy. The anti-tumor performance of apatinib was hamstrung by its elevated toxicity at 35 °C. The addition of pemetrexed to anti-angiogenesis therapy had no obvious additional benefit in tumors.

J Thorac Oncol. 2015 Mar;10(3):486-91. (PMID: 25695221)
Cancer Sci. 2011 Jul;102(7):1374-80. (PMID: 21443688)
Cell Stem Cell. 2008 Feb 7;2(2):183-9. (PMID: 18371439)
Biochem Biophys Res Commun. 2007 Sep 14;361(1):79-84. (PMID: 17644065)
CA Cancer J Clin. 2018 Jan;68(1):7-30. (PMID: 29313949)
J Clin Oncol. 2008 Jul 20;26(21):3543-51. (PMID: 18506025)
Science. 2005 Jan 7;307(5706):58-62. (PMID: 15637262)
Assay Drug Dev Technol. 2016 Apr 5;:null. (PMID: 27045536)
Angiogenesis. 2006;9(3):139-51. (PMID: 17051341)
Angiogenesis. 2014 Jul;17(3):471-94. (PMID: 24482243)
Semin Oncol. 2003 Oct;30(5 Suppl 16):117-24. (PMID: 14613032)
Cancer Res. 2000 Nov 15;60(22):6253-8. (PMID: 11103779)
J Clin Oncol. 2005 Feb 10;23(5):1011-27. (PMID: 15585754)
Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11399-404. (PMID: 12177446)
Nature. 1990 Dec 6;348(6301):555-7. (PMID: 1701033)
Nature. 1997 Apr 17;386(6626):671-4. (PMID: 9109485)
Dev Biol. 2010 May 1;341(1):56-65. (PMID: 19895803)
J Clin Oncol. 2004 Jun 1;22(11):2184-91. (PMID: 15169807)
Clin Cancer Res. 2006 Nov 1;12(21):6573-84. (PMID: 17085673)
Cancer. 1995 Jun 15;75(12):2844-52. (PMID: 7773933)
Lancet Oncol. 2010 Aug;11(8):733-40. (PMID: 20650686)
Nat Rev Genet. 2007 May;8(5):353-67. (PMID: 17440532)
Cancer Res. 2000 Apr 15;60(8):2178-89. (PMID: 10786682)
J Clin Oncol. 2016 May 1;34(13):1448-54. (PMID: 26884585)
Nat Rev Cancer. 2008 Aug;8(8):579-91. (PMID: 18596824)
Nat Protoc. 2007;2(11):2918-23. (PMID: 18007628)
Cancer Res. 1999 Oct 15;59(20):5209-18. (PMID: 10537299)
Sci Transl Med. 2012 Feb 8;4(120):120ra17. (PMID: 22277784)
N Engl J Med. 2002 Jan 10;346(2):92-8. (PMID: 11784875)
Cell. 1997 Jan 24;88(2):277-85. (PMID: 9008168)
Cancer Cell. 2015 Jun 8;27(6):751-3. (PMID: 26058074)
Nat Rev Drug Discov. 2004 May;3(5):391-400. (PMID: 15136787)
J Clin Oncol. 2006 Feb 10;24(5):769-77. (PMID: 16391297)
Cancer Metastasis Rev. 2007 Dec;26(3-4):433-41. (PMID: 17786539)
Nature. 1993 Apr 29;362(6423):841-4. (PMID: 7683111)
BMC Cancer. 2010 Oct 05;10:529. (PMID: 20923544)
Zhongguo Fei Ai Za Zhi. 2005 Aug 20;8(4):283-90. (PMID: 21108883)
J Clin Oncol. 2009 Mar 10;27(8):1227-34. (PMID: 19188680)
Nat Biotechnol. 2006 Jan;24(1):73-5. (PMID: 16327811)
World J Surg Oncol. 2012 Aug 24;10:170. (PMID: 22917490)
Front Physiol. 2016 Mar 08;7:56. (PMID: 27014075)
J Clin Oncol. 2013 Sep 10;31(26):3219-25. (PMID: 23918952)
Lancet Oncol. 2017 Oct;18(10):1307-1316. (PMID: 28919011)
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90. (PMID: 21296855)
Lancet Respir Med. 2017 May;5(5):435-444. (PMID: 28408243)
Eur J Pharmacol. 2009 Jul 1;614(1-3):1-6. (PMID: 19389394)
N Engl J Med. 1991 Jan 3;324(1):1-8. (PMID: 1701519)
N Engl J Med. 2006 Dec 14;355(24):2542-50. (PMID: 17167137)
J Mammary Gland Biol Neoplasia. 2001 Oct;6(4):487-95. (PMID: 12013537)
Lung Cancer. 2017 Apr;106:70-75. (PMID: 28285697)

0 (Angiogenesis Inhibitors)
0 (Antineoplastic Agents)
0 (Endostatins)
0 (Pyridines)
0 (Recombinant Proteins)
04Q9AIZ7NO (Pemetrexed)
2S9ZZM9Q9V (Bevacizumab)
5S371K6132 (apatinib)
GVG18ZDN65 (endostar protein)

Date Created: 20181028 Date Completed: 20191025 Latest Revision: 20191025

20240829

PMC6203857

10.1038/s41598-018-34030-5

30367145